A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors

Inclusion Criteria

• •Incurable advanced solid tumors that are no longer responding to conventional therapy or for which no effective therapy exists; at the RD of Part 1, an extension cohort up to 20 patients with metastatic breast cancer who are known to be BRCA mutation carriers will be enrolled.
• •Age 18 years or older
• •ECOG 0-2
• •Life expectancy ≥ 3 months
• •Evaluable disease
• •Adequate bone marrow function
• •Adequate renal function
• •Adequate liver function
• •At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities
• •Able to swallow capsules
• •At least 3 weeks from major surgery
• •Agree to practice effective contraception
• •Ability to understand and willingness to sign the informed consent form